Press "Enter" to skip to content

LGBT+ Investment Firm Gaingels Joins American Gene Technologies

American Gene Technologies, announced that Gaingels invested in the company. This investment is to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease.This investment places Gaingels, which is the leading investment syndicate in support of and representing the LGBTQ community and allies in the venture capital space and many other private investors who believe deeply in American Gene Technologies mission, rapid drug development platform, and gene and cell therapy programs for HIV, cancer, and PKU.

Gaingels is an investment network of 1000+ investors focused on high-growth venture-backed companies who embrace LGBT+ leadership. It works to support its portfolio companies in identifying and recruiting diverse leadership talent, fostering a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.

Jeff Galvin, CEO and Founder of American Gene Technologies said that diversity in every aspect of society and business leads to the best outcomes for all of humanity. This place is where smart, motivated people of every background thrive to be our team, investors, and the populations we serve are all diverse. The company is proud to partner with Gaingels to accelerate solutions to the market and to achieve success for patients and investors alike. This investment is symbolic to us at American Gene Technologies. Our science, mission, and team present opportunities and products that uplift everyone without regard to background, lifestyle, or identity.

Lorenzo Thione, Managing Director of Gaingels said that as the largest investor network it is focused on supporting and investing in the best venture-backed companies that embrace and value diverse leadership, including LGBTQ+. Gaingels is also proud to participate in this mission. Its mission hits uniquely close to home for the LGBTQ+ community given the Gene company to focus on creating functional immunity and thus an effective cure for HIV.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *